SEC Filings

Investors

Overview
News & Events
Presentations
Company Info
Analyst Coverage
Financial Info
Stock Data
SEC Filings
SEDAR+
Legend Removal
Governance

SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings

Latest Quarterly or Annual Filing

10-Q

July 12, 2024

Quarterly report pursuant to Section 13 or 15(d)

3 2024
Quarter Results

10-Q Filing

PDF HTML

XBRL

ZIP XLS HTML

View PDF View HTML

Latest Current Report

8-K

October 2, 2024

Current report filing

View PDF View HTML

Latest Proxy Statement

DEF 14A

March 6, 2024

Definitive proxy statements

View PDF View HTML

View All SEC Filings

View and filter by group or type

View All Filings

Email Alerts
Contacts
RSS News Feed

Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
info@lexariabioscience.com

Canadian Operations
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

US Operations
105 Peach State Court, Suite A
Tyrone, GA 30290

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Back to the top

Latest Quarterly or Annual Filing

Related Documents

3 2024Quarter Results

Latest Current Report

Latest Proxy Statement

View All SEC Filings

3 2024
Quarter Results